Buchwald–Hartwig amination

Buchwald–Hartwig amination
Name	Buchwald–Hartwig amination
Type	Cross-coupling reaction
Catalyst	Palladium complexes
Discovered	1994
Discoverers	John F. Hartwig; Stephen L. Buchwald

Buchwald–Hartwig amination is a palladium-catalyzed cross-coupling reaction that forms carbon–nitrogen bonds between aryl halides and amines, transforming aryl electrophiles into anilines and related derivatives. Developed in the 1990s by John F. Hartwig and Stephen L. Buchwald, the reaction rapidly became central to modern synthetic organic chemistry and pharmaceutical process development. It connects to a broad network of organometallic methodology, influencing industrial routes and academic research across institutions and societies.

Introduction

The reaction was independently introduced by John F. Hartwig and Stephen L. Buchwald in the mid-1990s, building on foundational work in transition-metal catalysis such as the Heck reaction, the Suzuki reaction, and the Negishi coupling. It leverages palladium catalysts to couple aryl halides, sulfonates, or pseudohalides with primary or secondary amines under base-promoted conditions, with early reports appearing in journals associated with institutions like California Institute of Technology, Massachusetts Institute of Technology, and Harvard University. The methodology earned recognition through its rapid adoption by companies such as Pfizer, Bristol-Myers Squibb, and Merck & Co. for route diversification and late-stage functionalization during drug discovery.

Reaction Scope and Mechanism

Mechanistically, the catalytic cycle parallels other palladium-catalyzed cross-couplings like the Negishi coupling and the Suzuki reaction, proceeding through oxidative addition of an aryl halide to a Pd(0) species, coordination and deprotonation of an amine, and reductive elimination to forge the C–N bond. Key mechanistic studies from groups at Yale University, University of California, Berkeley, and ETH Zurich elucidated intermediates, kinetics, and the role of bases and solvents, linking to spectroscopic techniques developed at Brookhaven National Laboratory and Argonne National Laboratory. Competing pathways such as β-hydride elimination and catalyst deactivation were characterized in collaborations involving Stanford University and University of Cambridge.

Catalysts and Ligand Development

Ligand design has driven improvements in activity and selectivity, with influential ligand families including biaryl monophosphines developed by Stephen L. Buchwald and sterically demanding phosphines explored by researchers at Cornell University and Northwestern University. Other notable ligands and catalyst systems emerged from work at Imperial College London, University of Tokyo, and Max Planck Institute for Coal Research, encompassing N-heterocyclic carbenes, dialkylbiaryl phosphines, and palladacycles. Industrial collaborations with GlaxoSmithKline and Johnson & Johnson spurred ligand libraries and high-throughput screening platforms, while awards such as the Wolf Prize in Chemistry and Priestley Medal highlighted the field’s impact on synthetic practice.

Substrate Scope and Limitations

The transformation tolerates a wide array of aryl chlorides, bromides, iodides, and pseudohalides, and couples aliphatic and aromatic amines, including hindered and heterocyclic examples encountered in projects at Eli Lilly and Company and AstraZeneca. Limitations include poor reactivity with highly deactivated electrophiles, sensitivity to protic or coordinating functional groups common in molecules from Pfizer pipelines, and challenges in selective monoarylation of primary amines—issues addressed in protocols from Merck Research Laboratories and academic teams at University of Oxford. Heteroaryl substrates and polyfunctionalized building blocks used in collaborations with Roche and Novartis required tailored ligand and base choices to mitigate competing side reactions.

Synthetic Applications and Variants

Applications span small-molecule pharmaceuticals, agrochemicals, and materials chemistry, with case studies from Boehringer Ingelheim and academic syntheses at Columbia University demonstrating late-stage diversification. Variants include intramolecular cyclizations popularized in work from University of Illinois Urbana-Champaign and tandem sequences integrating the reaction with Heck reaction or Sonogashira coupling modules developed at University of California, San Diego. Enantioselective adaptations and C–N bond-forming processes adjacent to stereocenters were advanced by groups at California Institute of Technology and University of Pennsylvania, while continuous-flow implementations emerged from collaborations involving MIT and ETH Zurich for process intensification.

Reaction Conditions and Practical Considerations

Typical conditions employ Pd(0) precursors or in situ generated Pd species, ligands tailored from libraries created at Northwestern University and Harvard University, and bases such as sodium tert-butoxide or potassium phosphate; solvent choices reflect studies conducted at University of Wisconsin–Madison and Yale University. Scale-up considerations addressed by Pfizer and GlaxoSmithKline emphasized air-stable precatalysts, ligand economy, and waste minimization consistent with guidelines from Environmental Protection Agency and industry best practices promoted by American Chemical Society. Troubleshooting routes from consortiums including Royal Society of Chemistry recommended base and ligand screens, inert atmosphere techniques taught at University of California, Los Angeles, and analytical monitoring approaches used at Sandia National Laboratories.

Category:Organic reactions